PL4117667T3 - Sekwencyjne leczenie nowotworów z użyciem 6-tio-dg i inhibitorów punktu kontrolnego - Google Patents

Sekwencyjne leczenie nowotworów z użyciem 6-tio-dg i inhibitorów punktu kontrolnego

Info

Publication number
PL4117667T3
PL4117667T3 PL21767125.4T PL21767125T PL4117667T3 PL 4117667 T3 PL4117667 T3 PL 4117667T3 PL 21767125 T PL21767125 T PL 21767125T PL 4117667 T3 PL4117667 T3 PL 4117667T3
Authority
PL
Poland
Prior art keywords
thio
cancers
checkpoint inhibitors
sequential treatment
sequential
Prior art date
Application number
PL21767125.4T
Other languages
English (en)
Inventor
Jerry Shay
Yang-Xin Fu
Ilgen MENDER
Anli ZHANG
Original Assignee
The Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Regents Of The University Of Texas System filed Critical The Board Of Regents Of The University Of Texas System
Publication of PL4117667T3 publication Critical patent/PL4117667T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
PL21767125.4T 2020-03-13 2021-03-12 Sekwencyjne leczenie nowotworów z użyciem 6-tio-dg i inhibitorów punktu kontrolnego PL4117667T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062989041P 2020-03-13 2020-03-13
PCT/US2021/022090 WO2021183873A1 (en) 2020-03-13 2021-03-12 Sequential treatment of cancers using 6-thio-dg, checkpoint inhibitors and radiation therapy

Publications (1)

Publication Number Publication Date
PL4117667T3 true PL4117667T3 (pl) 2025-04-07

Family

ID=77671975

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21767125.4T PL4117667T3 (pl) 2020-03-13 2021-03-12 Sekwencyjne leczenie nowotworów z użyciem 6-tio-dg i inhibitorów punktu kontrolnego

Country Status (17)

Country Link
US (2) US12097213B2 (pl)
EP (1) EP4117667B1 (pl)
JP (1) JP7829491B2 (pl)
KR (1) KR20220154134A (pl)
CN (1) CN115397428A (pl)
AU (1) AU2021233023A1 (pl)
BR (1) BR112022018238A2 (pl)
CA (1) CA3170930A1 (pl)
DK (1) DK4117667T3 (pl)
ES (1) ES3014683T3 (pl)
FI (1) FI4117667T3 (pl)
HU (1) HUE070513T2 (pl)
IL (1) IL296403A (pl)
MX (1) MX2022011331A (pl)
PL (1) PL4117667T3 (pl)
PT (1) PT4117667T (pl)
WO (1) WO2021183873A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025090539A1 (en) * 2023-10-22 2025-05-01 Regeneron Pharmaceuticals, Inc. Treatment of non-small cell lung cancer with 6-thio-dg and cemiplimab

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2812500A1 (en) * 2010-10-22 2012-04-26 Simone Budow A conjugate between a thiophilic solid phase and an oligonucleotide comprising a thiooxonucleotide
EP2983675A2 (en) 2013-04-08 2016-02-17 The Board of Regents of The University of Texas System Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere
CN116059219A (zh) * 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
WO2017165675A1 (en) * 2016-03-24 2017-09-28 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
EP3463370A4 (en) * 2016-05-27 2020-04-08 The Board of Regents of The University of Texas System 6-THIO-2'-DEOXYGUANOSINE (6-THIO-DG) RESULTS IN TELOMERASE-DEPENDENT TELOMER DYS FUNCTION AND CELL DEATH IN THERAPY-RESISTANT CANCER CELL
AU2017326751B2 (en) * 2016-09-16 2024-10-10 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
IL321717A (en) * 2017-02-21 2025-08-01 Regeneron Pharma Anti-PD-1 antibodies for the treatment of lung cancer
JP2020515637A (ja) 2017-04-03 2020-05-28 オンコロジー、インコーポレイテッド 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法
WO2019152574A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
US20210113602A1 (en) 2018-02-28 2021-04-22 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-2'-DEOXYGUANOSINE (6-THIO-dG) TO TREAT MELANOMA
WO2019183482A1 (en) * 2018-03-22 2019-09-26 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS

Also Published As

Publication number Publication date
US12097213B2 (en) 2024-09-24
JP2023517671A (ja) 2023-04-26
JP7829491B2 (ja) 2026-03-13
US20240424013A1 (en) 2024-12-26
EP4117667A1 (en) 2023-01-18
ES3014683T3 (en) 2025-04-24
EP4117667B1 (en) 2024-12-18
EP4117667A4 (en) 2023-11-15
DK4117667T3 (da) 2025-02-10
KR20220154134A (ko) 2022-11-21
MX2022011331A (es) 2022-10-27
CA3170930A1 (en) 2021-09-16
US20210290652A1 (en) 2021-09-23
FI4117667T3 (fi) 2025-02-10
HUE070513T2 (hu) 2025-06-28
CN115397428A (zh) 2022-11-25
WO2021183873A1 (en) 2021-09-16
IL296403A (en) 2022-11-01
BR112022018238A2 (pt) 2022-10-25
AU2021233023A1 (en) 2022-11-03
PT4117667T (pt) 2025-02-06

Similar Documents

Publication Publication Date Title
IL325094A (en) PI3K-alpha inhibitors and methods of using them
IL284324A (en) Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer
IL284326A (en) Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer
IL304294A (en) Pharmaceutical combinations of sos1 inhibitors for the treatment and/or inhibition of cancer
IL288395A (en) Mat2a tricyclic inhibitors and methods for use in cancer therapy
IL277665A (en) Heterocyclic inhibitors of MAT2A and methods of use for cancer therapy
PT4181920T (pt) Inibidor de kat6 e combinações para o tratamento do cancro da mama
IL312348A (en) HIF-2ALPHA inhibitors and methods of using it
IL304680A (en) Urolithin history and methods of using them
IL325232A (en) PI3K inhibitors and their use
IL318169A (en) Apol1 inhibitors and methods of use are the same
IL287973A (en) acss2 inhibitors and methods of their use
IL304728A (en) cdk2 inhibitors and methods of using them
IL316619A (en) PI3Kα inhibitors and methods of using them
IL314320A (en) Compounds and methods of use
IL299700B1 (en) KCNT1 inhibitors and methods of use
HUE067894T2 (hu) Mirdametinib és lifirafenib együttes beadása rákos megbetegedések kezelésében történõ alkalmazásra
IL312466A (en) PI3K-alpha inhibitors and methods for their preparation and use
IL287043B2 (en) Notch signaling pathway inhibitors and their use in cancer treatment
IL318393A (en) Azaquinazoline compounds and methods of use
ZA202202617B (en) Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor
HUE070513T2 (hu) Rákos megbetegedések szekvenciális kezelése 6-tio-DG és checkpoint-inhibitorok alkalmazásával
IL314277A (en) Anti-B7-H3 compounds and methods of use
IL321255A (en) ADAR1 inhibitors and methods of using them
IL286699A (en) Atypical protein c kinase inhibitors and their use in the treatment of hedgehog pathway-dependent cancers